Reports Q2 revenue $811M, consensus $774.68M. The company said, “The Exact Sciences (EXAS) team continues to build momentum, advancing our mission through earlier detection. In the second quarter, we delivered answers to more patients than ever drivenby strong momentum behind the successful launch of Cologuard Plus, powerful commercial execution, andexceptional customer satisfaction. This progress strengthens our platform and enables us to deliver better outcomes for patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences’ Growth Potential Bolstered by Cologuard Plus and Strategic Medicare Advantage Agreement
- EXAS Upcoming Earnings Report: What to Expect?
- Exact Sciences expands colorectal cancer screening partnership with Humana
- Buy Rating for Exact Sciences Driven by Promising CRC Screening Test and Favorable Market Outlook
- Exact Sciences’ Innovative PCR-Based Blood Test Positions Company for Market Leadership in Colorectal Cancer Screening